[go: up one dir, main page]

GB201120993D0 - Novel compounds and their use in therapy - Google Patents

Novel compounds and their use in therapy

Info

Publication number
GB201120993D0
GB201120993D0 GBGB1120993.9A GB201120993A GB201120993D0 GB 201120993 D0 GB201120993 D0 GB 201120993D0 GB 201120993 A GB201120993 A GB 201120993A GB 201120993 D0 GB201120993 D0 GB 201120993D0
Authority
GB
United Kingdom
Prior art keywords
therapy
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1120993.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Innovations Ltd filed Critical Imperial Innovations Ltd
Priority to GBGB1120993.9A priority Critical patent/GB201120993D0/en
Publication of GB201120993D0 publication Critical patent/GB201120993D0/en
Priority to PCT/GB2012/053041 priority patent/WO2013083991A1/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1120993.9A 2011-12-06 2011-12-06 Novel compounds and their use in therapy Ceased GB201120993D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1120993.9A GB201120993D0 (en) 2011-12-06 2011-12-06 Novel compounds and their use in therapy
PCT/GB2012/053041 WO2013083991A1 (en) 2011-12-06 2012-12-06 Novel compounds and their use in therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1120993.9A GB201120993D0 (en) 2011-12-06 2011-12-06 Novel compounds and their use in therapy

Publications (1)

Publication Number Publication Date
GB201120993D0 true GB201120993D0 (en) 2012-01-18

Family

ID=45541311

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1120993.9A Ceased GB201120993D0 (en) 2011-12-06 2011-12-06 Novel compounds and their use in therapy

Country Status (2)

Country Link
GB (1) GB201120993D0 (en)
WO (1) WO2013083991A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX371331B (en) 2012-04-24 2020-01-27 Vertex Pharma Dna-pk inhibitors.
SI3527563T1 (en) 2013-03-12 2022-01-31 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
DK3424920T3 (en) 2013-10-17 2020-06-08 Vertex Pharma CO CRYSTALS OF (S) -N-METHYL-8- (1 - ((2'-METHYL- [4,5'-BIPYRIMIDIN] -6-YL) AMINO) PROPAN-2-YL) QUINOLIN-4-CARBOXAMIDE AND DEUTERATED DERIVATIVES THEREOF AS DNA-PK INHIBITORS
CN105315188B (en) * 2014-06-03 2018-10-16 武汉药明康德新药开发有限公司 A kind of preparation method of 2- (1- (tertbutyloxycarbonyl) azelidinyls -3-) ethylene-acetic acid
GB201511382D0 (en) * 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
JP2019529475A (en) 2016-09-27 2019-10-17 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Method for treating cancer using a combination of a DNA damaging agent and a DNA-PK inhibitor
JP7595413B2 (en) 2016-11-30 2024-12-06 ケース ウエスタン リザーブ ユニバーシティ Combination of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof - Patents.com
CA3052466A1 (en) 2017-02-06 2018-08-09 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
KR20250107972A (en) 2018-05-04 2025-07-14 레미디 플랜, 인크. Cancer treatments targeting cancer stem cells
CA3120858A1 (en) 2018-11-21 2020-05-28 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
GB201820659D0 (en) 2018-12-19 2019-01-30 Imperial Innovations Ltd Novel compostions and their use in therapy
GB201820660D0 (en) 2018-12-19 2019-01-30 Imperial Innovations Ltd Cancer treatments
JP7458406B2 (en) 2018-12-21 2024-03-29 セルジーン コーポレーション Thienopyridine inhibitor of RIPK2
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
CN114174283B (en) * 2019-07-18 2023-05-12 石药集团中奇制药技术(石家庄)有限公司 Compounds as NMT inhibitors and uses thereof
WO2021146370A1 (en) 2020-01-15 2021-07-22 Blueprint Medicines Corporation Map4k1 inhibitors
GB202014736D0 (en) 2020-09-18 2020-11-04 Imperial College Innovations Ltd Novel compounds and their use in therapy
GB202017367D0 (en) 2020-11-02 2020-12-16 Imperial College Innovations Ltd Novel use
KR20240083168A (en) 2021-07-14 2024-06-11 블루프린트 메디신즈 코포레이션 Heterocyclic compounds as MAP4K1 inhibitors
KR20250060207A (en) 2022-09-09 2025-05-07 미릭스 파마 리미티드 Antibody drug conjugates comprising NMT inhibitors and uses thereof
EP4644373A1 (en) * 2022-12-28 2025-11-05 Nippon Soda Co., Ltd. Hydrazide compound and agricultural/horticultural bactericidal agent
GB202403391D0 (en) 2024-03-08 2024-04-24 Myricx Pharma Ltd Novel compounds and their use in therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1149094B1 (en) 1998-12-18 2004-04-21 Basilea Pharmaceutica AG 4-(aminoalkoxy)benzofurans as n-myristoyltransferase inhibitors
US20040014764A1 (en) 2002-03-29 2004-01-22 Smith Charles D. N-myristoyltransferase inhibitor compositions and methods of use
EP1604988A1 (en) * 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
GB0815947D0 (en) 2008-09-02 2008-10-08 Univ Dundee Compounds

Also Published As

Publication number Publication date
WO2013083991A1 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
GB201120993D0 (en) Novel compounds and their use in therapy
EP2739144A4 (en) Compounds and therapeutic uses thereof
ZA201307797B (en) Bicyclic heterocycle compounds and their uses in therapy
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
ZA201403372B (en) Therapeutic agents and uses thereof
GB201111705D0 (en) Compounds and their use
IL231082A0 (en) Pyrimido - pyridazinone compounds and use thereof
PL2780332T3 (en) Morpholinylbenzotriazines for use in cancer therapy
GB201111630D0 (en) Novel compounds and their use
GB201218084D0 (en) Novel compounds and methods for use in medicine
GB201011411D0 (en) Therapeutic compounds and their use
GB201114448D0 (en) Compounds and their use
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
IL232809A0 (en) Isothiazolopyridine-2-carboxamides and their use as pharmaceuticals
GB201102226D0 (en) Inventions and therapy
GB201102221D0 (en) Inventions and therapy
GB201102215D0 (en) Inventions and therapy
GB201102232D0 (en) Inventions and therapy
GB201102234D0 (en) Inventions and therapy
GB201102213D0 (en) Inventions and therapy
GB201102239D0 (en) Inventions and therapy
GB201102231D0 (en) Inventions and therapy
GB201102227D0 (en) Inventions and therapy
GB201102228D0 (en) Inventions and therapy
GB201102222D0 (en) Inventions and therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)